Maravai LifeSciences Holdings, Inc. MRVI Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 29.3%+11.0pp | 18.3%-2.8pp | 21.1%-9.5pp | 30.5%-6.8pp | 37.3%-4.5pp | |
| Operating margin | -82.2%+33.7pp | -115.9%-15.0pp | -100.9%+44.1pp | -145%-35.1pp | -109.9%-19.0pp | |
| Net margin | -51.1%+19.3pp | -70.4%-7.5pp | -62.9%+24.7pp | -87.6%-20.3pp | -67.3%-11.4pp | |
| EBITDA margin | -57.7%+30.5pp | -88.2%-14.0pp | -74.2%+48.0pp | -122.2%-32.7pp | -89.5%-17.3pp | |
| Returns | ||||||
| Return on equity | -40.8%+7.8pp | -48.6%-7.7pp | -41%+14.0pp | -55%-9.2pp | -45.8%-6.7pp | |
| Return on assets | -12.5%+2.2pp | -14.7%-3.3pp | -11.4%+5.1pp | -16.4%-2.9pp | -13.5%-1.9pp | |
| Return on invested capital | -51.1%+7.1pp | -58.2%-2.5pp | -55.7%+25.0pp | -80.7%-10.1pp | -70.5%-13.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Inventory turnover | 3.2×-0.1× | 3.4×+0.2× | 3.2×0.0× | 3.2×+0.1× | 3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.9×-0.7× | 6.6×+1.3× | 5.3×+0.1× | 5.2×-0.8× | 6×-1.6× | |
| Quick ratio | 5×-0.7× | 5.7×+1.1× | 4.6×+0.1× | 4.5×-0.7× | 5.2×-1.5× | |
| Cash ratio | 3.9×-0.9× | 4.8×+0.9× | 4×+0.1× | 3.9×-0.6× | 4.5×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 1.3×-0.4× | 1.7×+0.2× | 1.5×+0.1× | 1.4×+0.3× | 1.1×-0.1× | |
| Debt-to-assets | 0.4×-0.1× | 0.5×0.0× | 0.4×0.0× | 0.4×+0.1× | 0.3×0.0× | |
| Interest coverage | -6.5×+1.5× | -8×-1.8× | -6.1×+2.2× | -8.3×-2.2× | -6.1×-1.2× | |
| Per Share | ||||||
| Book value per share | $1.44-1.8% | $1.47-13.3% | $1.70-8.0% | $1.84-12.1% | $2.10-11.1% | |
| Valuation | ||||||
| Market capitalization | $902.74M+204% | $471.32M+13.5% | $415.23M+29.3% | $321.07M+1.1% | $317.47M-58.9% | |
| Enterprise value | $1.01B+198% | $619.14M+14.7% | $539.59M+27.8% | $422.24M+17.6% | $359.07M-56.6% | |
| Price / sales | 4.4×+3.2× | 2.5×+0.4× | 2.2×+0.7× | 1.5×+0.1× | 1.3×-1.7× | |
| Price / book | 4.3×+3.3× | 2.2×+0.5× | 1.7×+0.5× | 1.2×+0.2× | 1.1×-1.3× | |
| EV / sales | 4.9×+3.5× | 3.3×+0.5× | 2.8×+0.9× | 1.9×+0.4× | 1.5×-1.7× | |
| Earnings yield | -11.6%+43.3pp | -27.7%+1.4pp | -29.1%+30.8pp | -60%-8.7pp | -51.3%-32.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Maravai LifeSciences Holdings, Inc.'s profit margins?
- Maravai LifeSciences Holdings, Inc. (MRVI) runs a 29.3% gross margin and a -82.2% operating margin, with a -51.1% net margin.
- Where do Maravai LifeSciences Holdings, Inc.'s ratios come from?
- Every ratio is computed from Maravai LifeSciences Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
